Site Editor
Sandy Srinivas, MD
Sandy Srinivas, MD
Posted: Friday, December 9, 2022
Yu Wei, PhD, of Fudan University Shanghai Cancer Centre, China, reported the greatest difference in mutation prevalence between prostate cancer from Chinese and White men was in metastatic castration-sensitive prostate cancer. Additionally, the lower frequency of FOXA1 class 2 mutations in Chinese patients with prostate cancer seemed to underscore the mechanistic difference in cancer progression between the races. These findings were presented at the European Society for Medical Oncology (ESMO) Asia Congress 2022 (Abstract 162MO).
“The most important differences we observed were concentrated in castration-sensitive disease and included lower mutation rates in prostate cancer driver genes such as TP53 and PTEN among Chinese patients compared to the Western cohorts, which may partially account for the better prognosis observed in Asian men in this setting,” said Dr. Wei in an ESMO press release.
A total of 1,016 Chinese patients, including 315 with locoregional prostate cancer, 313 with metastatic castration-sensitive prostate cancer, and 388 with metastatic castration-resistant prostate cancer, were enrolled in the study for targeted sequencing. Genomic data retrieved from The Cancer Genome Atlas, Memorial Sloan Kettering Cancer Center, and Stand Up to Cancer cohort were used as a comparator representing White patients.
Mutations were found in TP53, AR, and FOXA1 in metastatic castration-resistant prostate cancer. Patients with visceral metastasis harbored more APC mutations than did patients with bone metastasis. Genomic differences between the patient groups were mainly observed in metastatic castration-sensitive prostate cancer, with tumors from Chinese men having more FOXA1 but fewer TP53 mutations in locoregional prostate cancer and harboring fewer TP53, PTEN, and APC mutations in metastatic castration-resistant prostate cancer than those from White men. Additionally, FOXA1 class 2 mutations were less common in East Asian patients.
Disclosure: The study authors reported no conflicts of interest.
JNCCN Spotlights
